Upload
nguyendung
View
214
Download
0
Embed Size (px)
Citation preview
Finasteride | apollo | +9191 46 950 950
Finasteride | apollo | +9191 46 950 950
Finasteride
CAS Number : 98319-26-7
Molecular Weight : 372.549g/mol
Molecular Formula : C23H36N2O2
Systematic (IUPAC) : (1S,2R,7R,10S,11S,14S,15S)-N-tert-butyl-2,15-dimethyl-5-oxo-6-
azatetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-3-ene-14-carboxamide
DRUG DESCRIPTION
This medication is used to treat male pattern hair loss and is to be used only by adult men.
Finasteride is a white crystalline powder with a melting point near 250°C. It is freely soluble in chloroform and in lower alcohol solvents, but is practically insoluble in
water.
Finasteride tablets for oral administration are film-coated tablets that contain 5 mg of Finasteride and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, pregelatinised starch, docusate sodium, magnesium
stearate, hypromellose, hydroxypropyl cellulose, titanium dioxide, talc, iron oxide yellow
Finasterideis used alone or in combination with another medicationto treat benign prostatic hypertrophy (BPH,
enlargement of the prostate gland). Finasteride improves symptoms of BPH such as frequent and
difficult urination and may reduce the chance of acute urinary retention (suddenly being unable to pass urine).
It also may decrease the chance of needing prostate surgery. Finasterideis also used to treat male pattern
hair loss (a common condition in which men have gradual thinning of the hair on the scalp, leading to a receding hairline or balding on the top of the head.)
Finasteridehas not been shown to treat thinning hair at the temples and is not used to treat hair loss in women
or children. Finasteride is in a class of medications called 5-alpha reductase inhibitors. Finasteride treats
BPH by blocking the body's production of a male hormone that causes the prostate to enlarge. Finasteride
treats male pattern hair loss by blocking the body's production of a male hormone in the scalp that stops
hair growth.
DOSAGE
Finasteride comes as a tablet to take by mouth. It is usually taken once a day with or without food. Take
finasteride at around the same time every day. Follow the directions on your prescription label carefully, and
ask your doctor or pharmacist to explain any part you do not understand. Take finasteride exactly as directed. Do
not take more or less of it or take it more often than prescribed by your doctor.
If you are taking finasteride to treat BPH, you should know that finasteride controls your condition, but does
not cure it. It may take at least 6 months before your symptoms improve. Continue to take finasteride even if
you feel well. Do not stop taking finasteride without talking to your doctor.
If you are taking finasteride to treat male pattern hair loss, you should know that finasteride controls hair loss, but does not cure it. It may take at least 3 months before you see any benefit. Continue to take finasteride even if
you have already seen an effect. Do not stop taking finasteride without talking to your doctor. If you stop taking finasteride, you will probably lose the hair you
have regrown within 12 months of stopping your treatment.
If you are taking finasteride to treat male pattern hair loss and have not seen any improvement within 12
months, further treatment will probably not help. Talk to your doctor about whether you should continue your
treatment.
SIDE EFFECTS
Unlikely to occur but the possible side effects include impotence, decreased sex drive or decrease in amount of
ejaculate.
Finasteride may cause side effects.
* inability to have or maintain an erection
* decreased sexual desire
* decreased volume of ejaculate (amount of semen)
* pain in the testicles
Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately:
* changes in the breasts such as increased size, lumps, pain, or nipple discharge
* rash
* itching
* hives
* swelling of the lips and face
INTERACTION
No drug interactions of clinical importance have been identified. Finasteride does not appear to affect the cytochrome P450-linked drug metabolizing enzyme
system. Compounds that have been tested in man have included antipyrine, digoxin, propranolol, theophylline, and warfarin and no clinically meaningful interactions
were found.
Other Concomitant Therapy: Although specific interaction studies were not performed, Finasteride was
concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers,
angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking
agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal
anti-inflammatory drugs (NSAIDs), benzodiazepines, H2 antagonists and quinolone anti-infectives without evidence of clinically significant adverse interactions.
PHARMALOGY
The development and enlargement of the prostate gland is dependent on the potent androgen, 5α-
dihydrotestosterone (DHT). Type II 5α-reductase metabolizes testosterone to DHT in the prostate gland,
liver and skin. DHT induces androgenic effects by binding to androgen receptors in the cell nuclei of these
organs.
Finasteride is a competitive and specific inhibitor of Type II 5α-reductase with which it slowly forms a stable
enzyme complex. Turnover from this complex is extremely slow (t½ ~ 30 days). This has been
demonstrated both in vivo and in vitro. Finasteride has no affinity for the androgen receptor. In man, the 5α-
reduced steroid metabolites in blood and urine are decreased after administration of Finasteride.
In man, a single 5 mg oral dose of Finasteride produces a rapid reduction in serum DHT concentration, with the
maximum effect observed 8 hours after the first dose. The suppression of DHT is maintained throughout the 24-hour dosing interval and with continued treatment.
Daily dosing of Finasteride at 5 mg/day for up to 4 years has been shown to reduce the serum DHT concentration by approximately 70%. The median circulating level of testosterone increased by approximately 10 to 20% but
remained within the physiologic range.
Adult males with genetically inherited Type II 5α-reductase deficiency also have decreased levels of DHT. Except for the associated urogenital defects present at
birth, no other clinical abnormalities related to Type II 5α-reductase deficiency have been observed in these individuals. These individuals have a small prostate
gland throughout life and do not develop BPH.
In patients with BPH treated with Finasteride (1 to 100 mg/day) for 7 to 10 days prior to prostatectomy, an
approximate 80% lower DHT content was measured in prostatic tissue removed at surgery, compared to
placebo; testosterone tissue concentration was increased up to 10 times over pretreatment levels, relative to placebo. Intraprostatic content of prostate-specific
antigen (PSA) was also decreased.
In healthy male volunteers treated with Finasteride for 14 days, discontinuation of therapy resulted in a return of DHT levels to pretreatment levels in approximately 2
weeks. In patients treated for three months, prostate volume, which declined by approximately 20%, returned
to close to baseline value after approximately three months of discontinuation of therapy.
CONSUMER INFORMATION
USES
Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also
reduce the need for surgery.
HOW TO USE
Read the Patient Information Leaflet provided by your pharmacist before you start taking finasteride and each time you get a refill. If you have any questions regarding
the information, consult your doctor or pharmacist. SIDE
EFFECTS
Decreased sexual ability/desire may occur. In some men, this medication can decrease the amount of semen released during sex. This is harmless. Finasteride may also increase hair growth. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.
PRECAUTIONS
Before taking finasteride, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies.
MISSED DOSE
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose
and resume your usual dosing schedule. Do not double the dose to catch up.
STORAGE
Store US product at room temperature below 86 degrees F (30 degrees C) away from light and moisture in a
tightly closed container.
Store Canadian product at room temperature between 59 to 86 degrees F (15 to 30 degrees C) away from light
and moisture in a tightly closed container.
Do not store in the bathroom. Keep all medicines away from children and pets.
Type
small molecule
Description
An orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for
treatment of benign prostatic hyperplasia.
Synonyms
Finasterida [INN-Spanish]
Finasteridum [INN-Latin]
Categories
Enzyme Inhibitors
Skin and Mucous Membrane Agents
Anti-baldness Agents
Antihyperplasia Agents
Taxonomy
Kingdom Organic
Classes
Steroids and Steroid Derivatives
Lactams
Substructures
Steroids and Steroid Derivatives
Alkanes and Alkenes
Amino Ketones
Carboxylic Acids and Derivatives
Heterocyclic compounds
Carboxamides and Derivatives
Lactams
Pharmacology
Indication
For the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to:
Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery
including transurethral resection of the prostate. Also used for the stimulation of regrowth of hair in men with mild to moderate androgenetic alopecia (male pattern alopecia, hereditary alopecia, common male baldness).
Pharmacodynamics
Finasteride is a synthetic 4-azasteroid compound. This drug is a competitive and specific inhibitor of Type II 5a-
reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone
(DHT). Two distinct isozymes are found in mice, rats, monkeys, and humans: Type I and II. Each of these isozymes is differentially expressed in tissues and
developmental stages. In humans, Type I 5a-reductase is predominant in the sebaceous glands of most regions of
skin, including scalp, and liver. Type I 5a-reductase is responsible for approximately one-third of circulating DHT. The Type II 5a-reductase isozyme is primarily
found in prostate, seminal vesicles, epididymides, and hair follicles as well as liver, and is responsible for two-thirds of circulating DHT. Although finasteride is 100-fold more selective for type II 5a-reductase than for the
type I isoenzyme, chronic treatment with this drug may have some effect on type I 5a-reductase.
Mechanism of Action
The mechanism of action of Finasteride is based on its preferential inhibition of Type II 5a-reductase through
the formation of a stable complex with the enzyme. Inhibition of Type II 5a-reductase blocks the peripheral
conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT
concentrations, minimal to moderate increase in serum testosterone concentrations, and substantial increases in prostatic testosterone concetrations. As DHT appears to be the principal androgen responsible for stimulation of prostatic growth, a decrease in DHT concentrations will result in a decrease in prostatic volume (approximately
20-30% after 6-24 months of continued therapy). In men with androgenic alopecia, the mechanism of action has not been fully determined, but finasteride has shown to decrease scalp DHT concentration to the levels found
in hairy scalp, reduce serum DHT, increase hair regrowth, and slow hair loss.
Metabolism
Drug is extensively metabolized, primarily in the liver via CYP3A4. Two metabolites have been identified with
≤20% of the activity of finasteride.
Route of Elimination
Following an oral dose of 14C-finasteride in man (n = 6), a mean of 39% (range, 32 to 46%) of the dose was
excreted in the urine in the form of metabolites; 57%
(range, 51 to 64%) was excreted in the feces. Urinary excretion of metabolites was decreased in patients with renal impairment. This decrease was associated with an
increase in fecal excretion of metabolites.
Affected Organisms
Humans and other mammals
apollo | asia Division
apollo Pharmaceuticals INDIA [P] Ltd|asia Division
Mr.Vipin Saxena|CEO
DIRECT:+912265785588
Wireline Purchase HELPDESK:
+91-22-65050001
+91-22-65650001
Wireline Sales HELPDESK:
+91-22-65500009
+91-22-65050009
Wireless 24x7 HELPDESK:
+9191-46-951951
+9191-46-950950
Blackberry Pin :
32E6500D | 32E65010 | 28415C58
Email:
www.apollo.mn
www.apollo.com.co
www.apollopharmaceuticals.com
Chat:
MSN Hotmail:VipinrSaxena
Skype NAME:VipinrSaxena
Rocketmail:VipinrSaxena
Google mail:VipinrSaxena
BlackBerry:28415C58
Regd. Office :-
1104, Maker Chamber V,
Nariman Point
Mumbai, INDIA
Pin:400021
Industrial Office
D-62, OIC India
Oshiwara Industrial Centre,
New Link Road,
Goregoan West,
Mumbai, INDIA
Pin:400104
Manufacturing Unit Address:
Plot No. 117A,
Village: Chamble
Near MonaTona Limited.Wada,
Maharashtra,
PIN : 421312 | INDIA
Email:
www.apollo.mn | www.apollo.com.co | www.apollopharmaceuticals.Com